loading
Our Vision
Re-defining
Medicine for the Coming
Generation
Curing incurable diseases by re-programming cell fate or function.
Passionate
Reliable
Achievers
Committed
Team players
Innovative
Courageous
Engaged
iRegene's
mission
We are a passionate team committed
to developing first-in-class therapies
for patients suffering from major
incurable diseases. Making fast-acting
and disease-reversing therapies accessible
to patients in the greatest extent
possible is our priority.
Passionate
Achievers
Team players
Courageous
Reliable
Committed
Innovative
Engaged
Next Generation R&D Eco-system, Made by iRegene
iReMeta
Discovering Omics, Powered by AI
iReChem
Deep Learning Assisted Virtual Screening
iReXam
Compounds Validation
iReDita
Gene Editing & Reporter Cell Lines
iReCena
Designing Exosomes for Therapeutics Delivery
Pipelines
Project
Indication
IND Phase I Phase II Phase III
RIGHT
NouvNeu001
Parkinson′s Disease
Phase ll trial started in China, to be completed no later than Q4 2026;
US phase l trial started, estimated patient enrolment Q3 2025
NouvNeu003
Early-onset Parkinson's
IND approved by the NMPA on Dec 11th 2023; Finished phase l dosing in Mar 2025
NouvNeu004
Multiple System Atrophy
Submitted IND application to both NMPA and FDA in Q2 2025
NouvSight001
Retinal Degenerative Diseases
FDA ODD approved on Mar 20th 2024. IND will be submitted around Q4 2025
NouvNeu002
Ischemic Stroke
IND will be submitted around Q4 2025
Contact
iReMeta
Discovery Platform with the aid of AI Algorithms
• Omic analysis
• Information Learned from Patients
• Precise and distinctive models
Address
No. 9, Gaokeyuan 3rd Road, East Lake High-tech Development Zone, Wuhan
Tel.
(+86) 027-65522933 (+86) 13027159984
iregene@iregene.com
Address
218 Sang Tian Rd. BLDG 2 Rm.501 BioBAY Phase 2, Su Zhou Industrial Park Su Zhou, Jiang Su Province, 215000, China
Tel.
(+86) 186-9612-5803
iregene@iregene.com
Address
8000 Aarhus C, Denmark
iregene@iregene.com
Address
160 Robinson Road,#14-04 Singapore Business Federation Centre – Singapore 068914
iregene@iregene.com
www.iregene.com